Drug that helps adults addicted to opioid drugs also relieves withdrawal symptoms in newborns
2010-10-07
(Press-News.org) (PHILADELPHIA) - Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.
In the October 6th online issue of Addiction, the researchers say that using buprenorphine in a dozen addicted infants was both safe and successful and reduced days of treatment by 40 percent, compared to use of morphine in 12 other infants randomized to this treatment. The difference was 23 days of treatment versus 38 days.
"Given further study, such a beneficial drug could provide a new standard of treatment in a field where a well-defined therapeutic approach doesn't exist," says the study's lead author, Walter Kraft, M.D., associate professor in the Department of Pharmacology and Experimental Therapeutics at Jefferson.
"Not only do we think buprenorphine is an excellent choice to treat neonatal opioid withdrawal, but it may prove to also be cost effective," he says. "There are not good numbers to work with but we estimate up to 16,000 infants each year are at risk for the syndrome. If you assume the costs for this treatment are $2,000 a day over an average 30 days of hospitalization, annual charges for this treatment can be up to $1 billion."
"If we were to reduce hospital stay by just 20 percent, that would save $150 million," Dr. Kraft adds.
The investigative team, which includes experts in neonatology, addictions, clinical pharmacology and pediatric neurology are the first physicians to test buprenorphine in newborns. Buprenorphine is finding increased use in the treatment of adults with opioid dependence.
In infants, the agent was given sublingually – under the tongue – and to keep it there until it is absorbed, the physicians gave the babies pacifiers to suck. "This is the only report of a sublingual drug ever used in infants," Kraft says.
Many of the mothers of the infants receive care at the Family Center, which cares for the majority of pregnant opioid-addicted women in the Philadelphia area, Dr. Kraft says. The program is directed by co-author Karol Kaltenbach, Ph.D., who is a internationally known expert in the treatment of pregnant women with addiction.
In 2008, the research team published results from their first cohort using buprenorphine in infants. In this study, they enrolled 24 infants, half randomized to buprenorphine and half to standard of care oral morphine. The investigators found that infants treated with buprenorphine had a 23-day length of treatment, compared to 38 days for those treated with morphine. Length of hospital stay in the buprenorphine group was 32 days versus 42 in infants treated with morphine.
"They say that to truly know if buprenorphine is a better treatment for these infants, it will be necessary to conduct a double-blind randomized study in which physicians do not know which treatment has been administered. We are not using buprenorphine in infants who need treatment until we conduct this final step," Dr. Kraft says. "It is important to do the study in the most rigorous way possible, to prove the benefit of the therapy. We are currently in the planning stages of such a study."
INFORMATION:
Other co-authors include neonatologists Kevin Dysart, M.D.; Eric Gibson, M.D.; Jay Greenspan, M.D., chairman of the Department of Pediatrics; and Michelle Ehrlich, M.D., a pediatric neurologist.
The project was supported by the Commonwealth of Pennsylvania Tobacco Fund and the National Institute on Drug Abuse.
ELSE PRESS RELEASES FROM THIS DATE:
High risk of acute mountain sickness on Mount Kilimanjaro
2010-10-07
New Rochelle, NY, October 6, 2010 –Climbers of high peaks such as Mount Kilimanjaro are at high risk for Acute Mountain Sickness (AMS). Trekkers should not ignore AMS warning signs, which can progress to more serious medical outcomes. Mountain climbers can best minimize their risk for altitude sickness by becoming acclimatized to increased altitudes before an ascent, according to a study in the current issue of High Altitude Medicine & Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/ham
The ...
Novel reference material to standardize gene therapy applications
2010-10-07
New Rochelle, NY, October 6, 2010—The introduction of a new, fully characterized viral vector for use as reference material to help standardize gene therapy protocols in research applications and human clinical trials is described in an article in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article, which is published online ahead of print, is available free online at www.liebertpub.com/hum
The growing popularity in the gene therapy community of using recombinant adeno-associated virus (rAAV) vectors as vehicles ...
Scripps Research scientists develop novel test that identifies river blindness
2010-10-07
LA JOLLA, CA – October 6, 2010 – For Immediate Release – Scientists from The Scripps Research Institute have developed the first screening method that rapidly identifies individuals with active river blindness, a parasitic disease that afflicts an estimated 37 million people. The test could change the current strategy of mass treatment in areas where river blindness, also known as onchocerciasis, is suspected.
The study was published online on October 5, 2010, by the journal PLOS Neglected Tropical Diseases.
"A sensitive and reproducible diagnostic test for this disease ...
Neighborhoods can have depressing effect on health, according to Iowa State study
2010-10-07
AMES, Iowa -- The nation's poverty rate climbed to 14.3 percent -- the highest level since 1994 -- according to the Census Bureau's annual report on the economic well-being of U.S. households. That means one in seven Americans now live in poverty, and that may have an especially depressing effect on people living in bad neighborhoods, according to two Iowa State University researchers.
Daniel Russell, an Iowa State professor of human development and family studies; and Carolyn Cutrona, professor and chair of psychology, presented "Stressful Effects of Where You Live: ...
UD researcher on project team for NASA's first visit to the sun
2010-10-07
A University of Delaware researcher is helping to design instruments for a robotic space probe that will go where no other has gone before: the sun.
William Matthaeus, professor of physics and astronomy at UD, is involved in NASA's Solar Probe Plus project, which is slated to launch by 2018.
The unmanned spacecraft, the size of a small car, will plunge directly into the sun's atmosphere to help uncover answers to perplexing mysteries about the fiery ball of plasma at the center of our solar system.
"The experiments selected for Solar Probe Plus are specifically designed ...
Iowa State team calculates societal costs of five major crimes; finds murder at $17.25 million
2010-10-07
AMES, Iowa -- Murder takes an obvious toll on society in terms of the loss of human life, but what does it actually cost each time there's a murder? It's about $17.25 million according a recent Iowa State University study.
Matt DeLisi, an ISU associate professor of sociology and director of the criminal justice program, led a team of five Iowa State graduate students on the study of 654 convicted and incarcerated murderers. Expanding upon earlier monetization estimates, they calculated the costs of five crimes -- murder, rape, armed robbery, aggravated assault and burglary ...
Hormone acting as 'molecular glue' could boost plant immune systems
2010-10-07
EAST LANSING, Mich. — The discovery of a hormone acting like molecular glue could hold a key to bolstering plant immune systems and understanding how plants cope with environmental stress.
The study, which is featured in the Oct. 6 issue of Nature, reveals how the plant hormone jasmonate binds two proteins together – an emerging new concept in hormone biology and protein chemistry. The study also identifies the receptor's crystal structure to provide the first molecular view of how plants ward off attacks by insects and pathogens.
In short, the work explains how a highly ...
Patient-provider language barriers linked to worse diabetes control
2010-10-07
Patients who cannot discuss their diabetes with a doctor in their own language may have poorer health outcomes, even when interpreter services are available, according to a new study by researchers at UCSF and the Kaiser Permanente Division of Research.
The study found that, among Latino diabetes patients with limited English skills, those seen by non-Spanish speaking doctors were nearly twice as likely to have poor control of their blood sugar than those whose doctors spoke Spanish.
Findings will appear in the January 2011 issue of the Journal of General Internal ...
Vitamin D-ficiency common among orthopaedic surgery
2010-10-07
Forty-three percent of patients scheduled to undergo orthopaedic surgery have insufficient levels of vitamin D and two out of five of those patients had levels low enough to place them at risk for metabolic bone disease, according to a study published this month in the October 6th issue of the Journal of Bone and Joint Surgery (JBJS).
According to the National Institutes of Health (NIH) , vitamin D helps the body absorb calcium and is essential for bone growth and bone remodeling. Without sufficient vitamin D, bones can become thin, brittle or misshapen. People can obtain ...
Study provides data that can inform Atlantic sturgeon recovery efforts
2010-10-07
STONY BROOK, NY, October 6, 2010 - A first-of-its-kind study that tracked the oceanic migrations of adult Atlantic sturgeon that were caught and tagged in the Hudson River discovered that these fish move vast distances in the Atlantic Ocean, traveling as far south as Georgia and as far north as Nova Scotia, Canada. The findings indicate that recovery of Atlantic sturgeon fisheries will need to address long-range oceanic threats to the species in addition to local measures closer to spawning grounds. These results are particularly timely given the announcement on October ...